First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

• Published in: Clinical cancer research Vol. 25; no. 21; pp. 6309 - 6319
• Main Authors: Piha-Paul, Sarina A., Sachdev, Jasgit C., Barve, Minal, LoRusso, Patricia, Szmulewitz, Russell, Patel, Sapna Pradyuman, Lara, Primo N., Chen, Xiaotian, Hu, Beibei, Freise, Kevin J., Modi, Dimple, Sood, Anjla, Hutti, Jessica E., Wolff, Johannes, O'Neil, Bert H.
• Format: Journal Article
• Language: English
• Published: United States 01.11.2019
• ISSN: 1078-0432; 1557-3265; 1557-3265
• DOI: 10.1158/1078-0432.CCR-19-0578

Bromodomain and extraterminal (BET) proteins play important roles in transcriptional regulation relevant to cancer pathogenesis, and therapeutic targeting/inhibition of BET causes apoptosis of cancer cells . In this first-in-human study of the pan-BET inhibitor mivebresib (ABBV-075), the safety prof...